Overexpression of Survivin has been shown to correlate negatively with DFS as well as overall survival in localized ccRCC.[22, 23] Five- and ten-year progression-free survival in the Survivin-positive group was 58.8% and 45.9%, respectively, compared with 86.8% and 81.2% in the Survivin-negative group.[22] A smaller study showed that patients with Survivin-positive RCC had higher recurrence rate at 5 years compared with Survivin-negative RCC (72% vs. 93%), with no difference in overall survival.[23]. The gene discussed is BIRC5; the disease is renal cell adenocarcinoma.